PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.12%
Negative revenue growth while Healthcare median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
21.56%
Gross profit growth of 21.56% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
123.81%
EBIT growth exceeding 1.5x Healthcare median of 0.55%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
123.81%
Operating income growth exceeding 1.5x Healthcare median of 1.71%. Joel Greenblatt would see if unique processes drive exceptional profitability.
645.04%
Net income growth exceeding 1.5x Healthcare median of 1.77%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
22200.00%
EPS growth exceeding 1.5x Healthcare median of 3.80%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
22200.00%
Diluted EPS growth exceeding 1.5x Healthcare median of 3.81%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
5.52%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.15%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-170.95%
Negative OCF growth while Healthcare median is 0.61%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-106.82%
Negative FCF growth while Healthcare median is 1.11%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
656.29%
5Y CAGR of 656.29% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
17.13%
3Y CAGR of 17.13% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-267.86%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-478.36%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-28.16%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
440.92%
Net income/share CAGR of 440.92% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
122.39%
Net income/share CAGR of 122.39% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
122.65%
3Y net income/share CAGR of 122.65% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
6526.78%
Equity/share CAGR of 6526.78% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
522.42%
5Y equity/share CAGR of 522.42% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
56.04%
3Y equity/share CAGR of 56.04% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.73%
AR growth of 5.73% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
17.28%
Inventory growth of 17.28% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
0.97%
We expand assets while Healthcare is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
-1.25%
Negative BV/share change while Healthcare median is -3.90%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.37%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-68.16%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
19.59%
Our SG&A slightly up while Healthcare is cutting. Peter Lynch wonders if we overspend or if the median underinvests in marketing.